70.60
前日終値:
$69.20
開ける:
$69.8
24時間の取引高:
3.00M
Relative Volume:
0.69
時価総額:
$41.45B
収益:
$5.72B
当期純損益:
$4.17B
株価収益率:
10.13
EPS:
6.97
ネットキャッシュフロー:
$259.90M
1週間 パフォーマンス:
-0.23%
1か月 パフォーマンス:
+0.20%
6か月 パフォーマンス:
+1.96%
1年 パフォーマンス:
-18.81%
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
EW を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-30 | アップグレード | Stifel | Hold → Buy |
2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
2024-07-25 | ダウングレード | Truist | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
2023-07-19 | 開始されました | Robert W. Baird | Outperform |
2023-05-30 | 再開されました | Morgan Stanley | Overweight |
2023-03-29 | 開始されました | UBS | Neutral |
2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-12-06 | ダウングレード | Stifel | Buy → Hold |
2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-10-26 | 開始されました | Mizuho | Buy |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Buy |
2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
2022-04-13 | 開始されました | Truist | Buy |
2022-04-06 | 開始されました | Wolfe Research | Outperform |
2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
2022-03-02 | 再開されました | BofA Securities | Neutral |
2022-02-02 | アップグレード | UBS | Neutral → Buy |
2022-01-27 | 繰り返されました | Citigroup | Buy |
2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | Stifel | Buy |
2022-01-27 | 繰り返されました | UBS | Neutral |
2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
2021-07-30 | 繰り返されました | Jefferies | Buy |
2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
2021-07-30 | 繰り返されました | Stifel | Buy |
2021-07-30 | 繰り返されました | UBS | Neutral |
2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
2020-09-11 | 開始されました | Wolfe Research | Underperform |
2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-10 | 開始されました | Oppenheimer | Outperform |
2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
2019-09-23 | 開始されました | Piper Jaffray | Overweight |
2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
2019-01-03 | 開始されました | Deutsche Bank | Hold |
2018-11-28 | 開始されました | UBS | Neutral |
2018-10-16 | 開始されました | Barclays | Underweight |
2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support? - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com Australia
Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - BioSpace
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa
Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech
Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - MarketScreener
Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards wins CE mark for Sapien M3 transfemoral heart valve - MassDevice
Breakthrough: First-Ever Transcatheter Mitral Valve Replacement Gets CE Mark Approval - Stock Titan
Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - marketscreener.com
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - marketscreener.com
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock By Investing.com - Investing.com Canada
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock - Investing.com
CMS rolls out draft coverage memo for TEER for the tricuspid valve - BioWorld MedTech
Citigroup Adjusts Edwards Lifesciences Price Target to $84 From $83, Maintains Buy Rating - MarketScreener
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session - Yahoo Finance
Edwards’ Early TAVR refutes surveillance recs for aortic stenosis - BioWorld MedTech
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Home
Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now! - Insider Monkey
Edwards shares data supporting timely TAVR intervention - MassDevice
Huntington Beach man meets heart valve engineers who saved his life - Los Angeles Times
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock By Investing.com - Investing.com South Africa
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):